Clinical Trials Browser

INDUSTRY × Multiple Myeloma × fludarabine × Clear all

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT04923893 2026-04-13

CARTITUDE-5

Phase 3 Active not recruiting

Multiple Myeloma

NCT06577025 2026-04-13

aMMbition

Phase 2 Active not recruiting

Multiple Myeloma

NCT07149857 2026-04-13

CARTITUDE-10

Phase 2 Recruiting

Multiple Myeloma

NCT06413498 2026-03-27

iMMagine-3

Phase 3 Recruiting

Multiple Myeloma

NCT06153251 2026-03-18

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT06045806 2026-03-05

KarMMa-9

Phase 3 Active not recruiting

Multiple Myeloma

NCT06325748 2026-02-12

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasmPlasma cell

Blastic Plasmacytoid Dendritic Cell Neoplasm, Multiple Myeloma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute

NCT04674813 2026-02-09

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma

NCT05182073 2025-12-12

FT576 in Subjects With Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05722418 2025-09-25

CaMMouflage

Phase 1 Recruiting

Multiple Myeloma

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT03994705 2025-05-15

Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1 Terminated

20 enrolled 12 charts

Multiple Myeloma

NCT05347485 2025-04-25

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Phase 2 Completed

86 enrolled 19 charts

Multiple Myeloma

NCT03448978 2024-07-01

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Phase 1 Terminated

Multiple Myeloma

NCT05000450 2024-06-28

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

Multiple Myeloma

NCT04025216 2024-01-24

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Phase 1 Terminated

BreastGynecologicPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03318861 2023-10-19

Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Terminated

17 enrolled 15 charts

Multiple Myeloma

NCT04171843 2023-09-21

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma

NCT04614636 2023-09-21

FT538 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Leukemia, Myeloid, Acute, Neoplasms, Plasma Cell

NCT04613557 2023-08-31

IMMUNICY-1

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT04196491 2023-08-23

KarMMa-4

Phase 1 Completed

Multiple Myeloma

NCT04093596 2023-08-14

UNIVERSAL

Phase 1 Active not recruiting

Multiple Myeloma

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Multiple Myeloma, Neoplasms, Recurrence

NCT03943472 2021-08-31

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Phase EARLY_PHASE1 Unknown

Multiple Myeloma

NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase EARLY_PHASE1 Unknown

Multiple Myeloma, Recurrence

NCT01500161 2013-11-25

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Phase 2 Terminated

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell